The Association of Serum Irisin with Bone Mineral Density and Turnover Markers in New-Onset Type 2 Diabetic Patients
Table 1
Clinical parameters of controls and T2DM subjects.
NGT (n = 82)
T2DM (n = 66)
t/χ2/Z
Gender, M/F
54/28
46/20
0.246
0.620
Age (years)
50.04 ± 8.98
51.08 ± 12.67
−0.562
0.575
SBP (mmHg)
126 (114,136)
123 (120,136)
−0.261
0.794
DBP (mmHg)
76 (69,87)
80 (75,88)
−2.118
0.034
Weight (kg)
69.01 ± 11.75
70.84 ± 14.18
−0.859
0.392
Height (cm)
166.54 ± 6.45
165.61 ± 8.46
0.760
0.449
BMI (kg/m2)
24.79 ± 3.25
25.69 ± 4.22
−1.479
0.141
Waist circumference (cm)
85.80 ± 9.22
89.07 ± 11.02
−1.965
0.051
Hip circumference (cm)
94.13 ± 5.46
92.45 ± 11.91
1.064
0.290
WHR
0.91 (0.87,0.96)
0.95 (0.91,1.00)
−3.586
<0.001
HbA1c (%)
5.4 (5.3,5.6)
8.0 (6.3,11.0)
−9.716
<0.001
FBG (mmol/L)
4.94 (4.64,5.31)
8.22 (5.92,12.69)
−8.608
<0.001
2hPG (mmol/L)
5.78 ± 1.22
16.38 ± 5.98
−14.165
<0.001
FINS (uIU/ml)
6.6 (4.8,9.4)
7.7 (4.5,11.0)
−1.468
0.142
HOMA-IR
1.45 (1.09,2.22)
2.90 (1,73,5.53)
−5.736
<0.001
HOMA-β
96.94 (62.98,147.71)
36.18 (14.46,78.26)
−6.743
<0.001
TC (mmol/L)
4.90 ± 1.01
5.44 ± 1.40
−2.681
0.008
TG (mmol/L)
1.32 (0.98,2.14)
1.71 (1.14,3.11)
−3.075
0.002
LDL-C (mmol/L)
2.77 ± 0.83
2.85 ± 1.06
−0.537
0.592
HDL-C (mmol/L)
1.26 (1.11,1.49)
1.09 (1.00,1.24)
−3.761
<0.001
25(OH)D (ng/ml)
21.19 (15.66,27.01)
18.32 (14.33,23.18)
−1.832
0.067
Lumbar BMD (g/cm2)
1.12 ± 0.14
1.09 ± 0.16
1.151
0.251
P1NP (ng/ml)
44.52 (35.73,58.05)
36.42 (25.68,51.70)
−2.567
0.010
OC (ng/ml)
18.70 (15.56, 23.22)
16.15 (12.40,21.66)
−2.345
0.019
β-CTX (ng/L)
0.47 (0.33,0.65)
0.43 (0.26,0.59)
−0.172
0.864
Irisin (ng/ml)
11.69 ± 2.06
10.90 ± 1.88
2.402
0.018
Values were given as means ± SD or median with interquartile range. NGT, normal glucose tolerance; T2DM, type 2 diabetes mellitus; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; WHR, waist-hip ratio; HbA1c, glycosylated hemoglobin A1c; FBG, fasting plasma glucose; 2hPG,2-hour plasma glucose; FIN, fasting insulin; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell function; TC, total cholesterol; TG, triglyceride, LDL-C, low-density lipoprotein; HDL-C, high-density lipoprotein; Lumbar BMD, body mineral density of the L1–L4 vertebrae. P1NP, procollagen type 1 intact N-terminal propeptide; OC, osteocalcin; β-CTX, β-C-terminal telopeptides of type I collagen.
